UNSPSC 51311903: Rizaben

An anti-allergy agent.

UNSPSC 51311903 Rizaben is a Commodity code under which state and local governments procure pharmaceutical products, specifically naloxone and other prescription medications, for community health and pharmacy benefit programs. The recent opportunities show purchasing activity centered on naloxone acquisition for emergency response and opioid mitigation, generic multi-source pharmaceuticals for state employee and retiree health plans, and direct-to-manufacturer prescription fulfillment initiatives. Issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Procurement vehicles include competitive IFBs from individual counties, RFPs from state cooperative purchasing groups, and exploratory RFIs from state agencies seeking to reshape their pharmacy supply chain without relying on traditional pharmacy benefit managers or group purchasing organizations.

Activity under this code concentrates in Florida and Minnesota, with additional engagement from Texas HHS. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a July 26, 2023 response deadline and a two-year initial contract term with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026; MMCAP requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs for self-insured employee health plans, signaling potential reshaping of that state's pharmacy procurement strategy.